Last updated on October 2016

ACY-1215 + Nab-paclitaxel in Metastatic Breast Cancer


Brief description of study

This is a non-randomized phase 1 trial designed to determine the MTD and evaluate the safety and tolerability of ACY-1215 with nab-paclitaxel. Based on the activity profile of ACY-1215 in breast cancer, corresponding biomarker availability with the HDAC6 MR score, and its potential synergy with taxanes, these data support the rationale for testing the ability of ACY-1215 to improve the response rate for patients with metastatic breast cancer in combination with standard taxane chemotherapy.

Detailed Study Description

Breast cancer is the most common female cancer and the second most common cause of death in women. Women with hormone receptor-negative tumors that are associated with symptomatic visceral metastases, or hormone receptor-positive tumors that are refractory to endocrine therapy require cytotoxic chemotherapy for disease control. The standard of care for patients with metastatic breast cancer includes single agent taxane-based chemotherapy. Combination chemotherapy generally provides higher rates of objective response and longer time to progression, compared to single-agent chemotherapy. However, it is associated with increased toxicity and is of little survival benefit. There remains an unmet need for combination regimens incorporating new, effective and oftentimes less toxic targeted agents together with standard chemotherapy.

Clinical Study Identifier: NCT02632071

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Kevin Kalinsky, MD, MS

Columbia University Medical Center
New York City, NY United States
  Connect »

Charles Shapiro, MD

Mount Sinai Hospital
New York, NY United States
  Connect »